echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Efficiently distinguishing between good and malignant lung nodules, this new method may be tried

    Efficiently distinguishing between good and malignant lung nodules, this new method may be tried

    • Last Update: 2022-10-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    *For medical professionals only

    Eliminate the high false positive of CT scan, to hear what Professor Leung Wenhua said?


    With the popularity of low-dose CT scans, more and more people are "discovered" to have one or more nodules on their lungs, and the early manifestation of lung cancer is lung nodules


    Counteracts the risk of false positives on CT scans


    Lung cancer is one of the most common tumors, and early diagnosis is an effective way


    New combined screening model for higher clinical availability


    In addition to judging the accuracy and sensitivity of the PulmoSeek Plus model, Professor Liang's team also compared the existing lung nodule diagnosis models, such as the Mayo model and the Brock model



    Liang Wenhua

    Professor/PhD Supervisor/Deputy Chief Physician


    • Department of Thoracic Oncology, First Affiliated Hospital of Guangzhou Medical University

    • Winner of the National Youth Fund (Oncology), a young Pearl River scholar, and an outstanding young medical talent in Guangdong

    • Assistant to the President of Guangzhou Institute of Respiratory Health, Director of the Office of the National Center for Respiratory Medicine

    • Deputy Leader of the Lung Cancer Group of the State Key Laboratory of Respiratory Diseases

    • Chairman of the Immunotherapy Committee of Guangdong Society of Chest Diseases

    • Vice Chairman of the Precision Medicine and Molecular Diagnostics Branch of Guangdong Medical Association

    • He is a youth member of the Chinese Society of Clinical Oncology (CSCO), a member of the NSCLC Special Committee, and a member of the Lung Cancer Guidelines Expert Group

    • Associate Editor, Transl Lung Cancer Res, Editorial Board of J Thorac Dis and Ann Transl Med

    • Mainly engaged in the comprehensive diagnosis and treatment of lung cancer and clinical translational research


    • Won the ASCO Merit Award, People's Network 'Famous Doctor of the Country', CSCO National 35 Most Promising Young Oncologists, 2020 Ali Dharma Academy Green Orange Award (first place in medicine), as one of the main finishers, won the second prize of the National Science and Technology Progress Award, the innovation team, and the national innovation competition medal



    Literature references:

    [1]https://oncologypro.


    [2] Ostrowski M,Marjanski T,Rzyman W.



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.